Additional production systems yeasts

Attention has also focused upon a variety of additional production systems for recombinant biopharmaceuticals. Yeast cells (particularly Saccharomyces cerevisiae) display a number of characteristics that make them attractive in this regard. These characteristics include  

The practical potential of yeast-based production systems has been confirmed by the successful expression of a whole range of proteins of therapeutic interest in such systems. However, a number of disadvantages relating to heterologous protein production in yeast have been recognized. These include  

---

The structure of mannose-rich polysaccharide core in GL4 is close to that of yeast mannan (from Saccharomyces cerevisiae), which was inactive for IL-6 induction in a human peripheral whole-blood cells test system. This fact suggests that not the mannose moieties but other components, such as the lipophilic moiety and/or phosphates, are important for the activity. The lipophilic products in HF-hydrolysate of GL4 were then analyzed. In addition to peaks corresponding to the known fatty acids (C16 0, C18 1), two other unknown ion peaks at m/z 330 and 356 were found by FAB-MS (data not shown). 

In 1997, the technology was incorporated into Thiokol Corporation s waste treatment facility near Brigham City, Utah (D22204Y, p. A58). This system initially used brewer s yeast and a cheese-whey mixture as nutrient sources. In an effort to reduce costs, these additives were replaced with a carbohydrate by-product. As a result, chemical and nutrient costs dropped by more than 90%, from approximately 1.76 to 0.16 per pound of perchlorate removed (D22204Y, p. A59). 

---